Clinical trial
Efficacy and Long-Term Safety of Vildagliptin as Add-on Therapy to Metformin in Patients With Type 2 Diabetes
NCT00860288 is registered in ClinicalTrials.gov with Novartis Pharmaceuticals as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Efficacy and Long-Term Safety of Vildagliptin as Add-on Therapy to Metformin in Patients With Type 2 Diabetes
- Lead sponsor
- Novartis Pharmaceuticals
- Phase
- Phase 2/3
- Overall status
- Completed
- Start date
- February 28, 2009
- Completion date
- March 31, 2011
- Enrollment
- 1,988 (actual)
- Sites
- 187
Conditions
As the registry lists them; a condition with its own page is linked.